Tom 18, Nr 3 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-07-13
Wyświetlenia strony
1393
Wyświetlenia/pobrania artykułu
313
Arypiprazol w leczeniu tików ― analiza przeglądów systematycznych i metaanaliz
Psychiatria 2021;18(3):241-251.
Streszczenie
Tiki charakteryzują się występowaniem nagłych, powtarzających się, szybkich, nierytmicznych ruchów lub wokalizacji. Najczęściej obserwuje się je u dzieci i młodzieży. Mogą być objawem innych chorób, najczęściej zespołu Tourette’a, wyraźnie wpływając na jakość życia pacjentów. Arypiprazol należy do grupy atypowych leków przeciwpsychotycznych. Jest wskazany w leczeniu schizofrenii, a w Stanach Zjednoczonych został już zarejestrowany do leczenia zespołu Tourette'a. Dotychczas przeprowadzono wiele badań klinicznych z zastosowaniem arypiprazolu w leczeniu zaburzeń tikowych i zespołu Tourette’a, a ich wyniki podsumowano w co najmniej kilku przeglądach systematycznych i metaanalizach, wykazując skuteczność terapeutyczną i dobrą tolerancję leku. W przedstawionym przeglądzie podsumowano dotychczasowe obserwacje, wskazujące na przydatność arypiprazolu w leczeniu zaburzeń tikowych.
Słowa kluczowe: antagonista receptora dopaminowegoagonista receptora dopaminowegoatypowe leki przeciwpsychotycznearypiprazoltikizespół Tourette’a
Referencje
- Mogwitz S, Buse J, Wolff N, et al. Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents. ACS Chem Neurosci. 2018; 9(4): 651–672.
- Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009; 67(6): 475–483.
- Yang C, Hao Z, Zhang LL, et al. Comparative Efficacy and Safety of Antipsychotic Drugs for Tic Disorders: A Systematic Review and Bayesian Network Meta-Analysis. Pharmacopsychiatry. 2019; 52(1): 7–15.
- American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (wyd. 5), American Psychiatric Association Publishing, Washington, DC. 2013.
- Wang S, Wei YZ, Yang JH, et al. The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis. Psychiatry Res. 2017; 254: 24–32.
- Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012; 47(2): 77–90.
- Yang C, Yi Q, Zhang L, et al. Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15816.
- Cutler D, Murphy T, Gilmour J, et al. The quality of life of young people with Tourette syndrome. Child Care Health Dev. 2009; 35(4): 496–504.
- Malaty IA, Akbar U. Updates in medical and surgical therapies for Tourette syndrome. Curr Neurol Neurosci Rep. 2014; 14(7): 458.
- Egolf A, Coffey BJ. Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs Today (Barc). 2014; 50(2): 159–179.
- Roessner V, Plessen KJ, Rothenberger A, et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011; 20(4): 173–196.
- Murphy TK, Lewin AB, Storch EA, et al. American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice Parameter for the Assessment and Treatment of Children and Adolescents with Tic Disorders. J Am Acad Child Adolesc Psychiatry. 2013; 52: 1341–1359.
- Bachmann CJ, Roessner V, Glaeske G, et al. Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany. Eur Child Adolesc Psychiatry. 2015; 24(2): 199–207.
- Buse J, Schoenefeld K, Münchau A, et al. Neuromodulation in Tourette syndrome: dopamine and beyond. Neurosci Biobehav Rev. 2013; 37(6): 1069–1084.
- Singer HS. Motor control, habits, complex motor stereotypies, and Tourette syndrome. Ann N Y Acad Sci. 2013; 1304: 22–31.
- Farag M, Stern JS, Simmons H, et al. Serial pharmacological prescribing practices for tic management in Tourette syndrome. Hum Psychopharmacol. 2015; 30(6): 435–441.
- Rampello L, Alvano A, Battaglia G, et al. Tic disorders: from pathophysiology to treatment. J Neurol. 2006; 253(1): 1–15.
- Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997; 154(8): 1057–1062.
- Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 2003; 37(5): 687–694.
- Yoo HK, Lee JS, Paik KW, et al. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011; 20(3): 127–135.
- Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002; 302(1): 381–389.
- Shapiro DA, Renock S, Arrington E, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999; 20(6): 612–627.
- Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998; 18(2): 63–101.
- Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14(2): 87–96.
- Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995; 275(1): 101–113.
- Kikuchi T, Tottori K, Uwahodo Y, et al. 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597): A new antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995; 274: 329–336.
- Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002; 441(3): 137–140.
- Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8): 1400–1411.
- ABILIFY, Charakterystyka Produktu Leczniczego. https://www.ema.europa.eu/en/documents/product-information/abilify-epar-product-information_pl.pdf (27.06.2021).
- Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635–2647.
- Britnell SR, Jackson AD, Brown JN, et al. Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review. Clin Neuropharmacol. 2017; 40(6): 273–278.
- Ariens EJ. Affinity and rinsic Activity in the Theory of Competitive nhibition. I Problems and Theory. Arch Int Pharmacodyn Ther. 1954; 99(32): 49.
- Tamminga CA, Carlsson A, Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm (Vienna). 2002; 109(3): 411–420.
- Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpriole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology. 1997; 321(1): 105–111.
- Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther. 1996; 277(1): 137–143.
- Momiyama T, Amano T, Todo N, et al. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol. 1996; 310(1): 1–8.
- Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (Berl). 1999; 146(2): 139–143.
- ABILIFY, Charakterystyka Produktu Leczniczego. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf (27.06.2021).
- Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014; 45(5): 596–603.
- Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358: j4008.
- Pringsheim T, Holler-Managan Y, Okun MS, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019; 92(19): 896–906.
